BeiGene Ltd.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: Tislelizumab
Drug: Ociperlimab

First Posted Date: 2021-01-05

Last Posted Date: 2023-10-27

Lead Sponsor: BeiGene

Target Recruit Count: 178

Registration Number: NCT04693234

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇧🇬
Medical center nadezhda clinical eood, Sofia, Bulgaria
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

and more 28 locations

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BGB-DXP604
Drug: BGB-DXP593
Drug: Placebo

First Posted Date: 2020-12-16

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 25

Registration Number: NCT04669262

Locations: 🇦🇺
Q PHARM, Herston, Queensland, Australia

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: BGB-15025
Drug: Tislelizumab

First Posted Date: 2020-12-02

Last Posted Date: 2025-01-09

Lead Sponsor: BeiGene

Target Recruit Count: 157

Registration Number: NCT04649385

Locations: 🇦🇺
One Clinical Research, Nedlands, Western Australia, Australia
🇰🇷
Seoul National University Hospital, Seoul, Seoul Teugbyeolsi, Korea, Republic of
🇺🇸
Icahn School of Medicine At Mount Sinai, New York, New York, United States

and more 19 locations

Zanubrutinib in Participants With Active Proliferative Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis

Interventions: Drug: Placebo
Drug: Zanubrutinib

First Posted Date: 2020-11-25

Last Posted Date: 2024-11-28

Lead Sponsor: BeiGene

Target Recruit Count: 177

Registration Number: NCT04643470

Locations: 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

and more 41 locations

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Placebo
Drug: BGB-DXP593

First Posted Date: 2020-09-16

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 181

Registration Number: NCT04551898

Locations: 🇺🇸
Btc Network Midland Florida Clinical Research Center, DeLand, Florida, United States
🇺🇸
Elixia Clinical Research Collaborative, Hollywood, Florida, United States
🇧🇷
Consultoria Medica E Pesquisa Clinica, Sorcaba, Brazil

and more 15 locations

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

Phase 1

Completed

Conditions: B-cell Malignancies

Interventions: Drug: Zanubrutinib
Drug: Fluconazole
Drug: Voriconazole
Drug: Diltiazem
Drug: Clarithromycin

First Posted Date: 2020-09-16

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 26

Registration Number: NCT04551963

Locations: 🇦🇺
Concord Repatriation General Hospital, Concord, New South Wales, Australia
🇦🇺
John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 4 locations

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants

Phase 1

Completed

Conditions: Covid19

Interventions: Drug: Placebo
Drug: BGB DXP593

First Posted Date: 2020-08-31

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 18

Registration Number: NCT04532294

Locations: 🇦🇺
Q PHARM, Herston, Queensland, Australia

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 3

Recruiting

Conditions: Classical Hodgkin Lymphoma

Interventions: Drug: Salvage Chemotherapy
Drug: Tislelizumab

First Posted Date: 2020-07-24

Last Posted Date: 2024-12-13

Lead Sponsor: BeiGene

Target Recruit Count: 123

Registration Number: NCT04486391

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

and more 4 locations

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Phase 1

Completed

Conditions: Tumor

Interventions: Drug: Sitravatinib

First Posted Date: 2020-07-15

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 26

Registration Number: NCT04472650

Locations: 🇦🇺
Linear Clinical Research, Nedlands, Western Australia, Australia

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males

Phase 1

Completed

Conditions: Healthy
Male

Interventions: Drug: Zanubrutinib
Drug: Rifabutin

First Posted Date: 2020-07-14

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 13

Registration Number: NCT04470908

Locations: 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy